Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Progress in the use of patient healthcare data is going slow for most countries, but some are racing ahead and setting the bar high. In Israel, the healthcare provider Maccabi has developed a system where researchers can access decades of medical records without compromising patient privacy. This incredible trove of medical data has given rise to groundbreaking academic and industry research, improving the lives of people around the world.
A woman opens her front door and looks to the sky to judge the weather. It’s sunny and inside her contact lenses, tiny microchips switch on layers of liquid crystals to protect her eyes from the bright light. Satisfied she won’t need a raincoat, the woman steps onto the street and goes about her day. It might sound like the start of a sci-fi novel, but this is the reality of Azalea Vision’s smart tech.
In the global search for more sustainable materials, one substance has recently begun attracting a lot of attention: mycelium, the white roots of fungi. VUB researcher Elise Elsacker has been studying the unique properties of mycelium and its potential for lowering environmental impact in the building and manufacturing industries, helping us move towards a circular economy.
It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug has been celebrated by some as a breakthrough for Alzheimer’s patients, but others remain highly sceptical or even openly opposed to the FDA decision. What has caused the furor? And what will this approval mean for other biotech companies developing new drugs for neurodegenerative diseases (and for the VCs backing them)?
Data without science is nothing; just 1s and 0s, floating around a cloud waiting for someone to make sense of them. Data science is the process of extracting value from data, using advanced analytics tools. Enormous amounts of health information are being gathered every second, and we are rapidly getting better at decoding it: turning bytes into insights that can be used to improve the lives of patients. But the pace, methods and ethics of data science adoption varies dramatically between countries and regions. Why should we care about keeping up?
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Progress in the use of patient healthcare data is going slow for most countries, but some are racing ahead and setting the bar high. In Israel, the healthcare provider Maccabi has developed a system where researchers can access decades of medical records without compromising patient privacy. This incredible trove of medical data has given rise to groundbreaking academic and industry research, improving the lives of people around the world.
A woman opens her front door and looks to the sky to judge the weather. It’s sunny and inside her contact lenses, tiny microchips switch on layers of liquid crystals to protect her eyes from the bright light. Satisfied she won’t need a raincoat, the woman steps onto the street and goes about her day. It might sound like the start of a sci-fi novel, but this is the reality of Azalea Vision’s smart tech.
In the global search for more sustainable materials, one substance has recently begun attracting a lot of attention: mycelium, the white roots of fungi. VUB researcher Elise Elsacker has been studying the unique properties of mycelium and its potential for lowering environmental impact in the building and manufacturing industries, helping us move towards a circular economy.
It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug has been celebrated by some as a breakthrough for Alzheimer’s patients, but others remain highly sceptical or even openly opposed to the FDA decision. What has caused the furor? And what will this approval mean for other biotech companies developing new drugs for neurodegenerative diseases (and for the VCs backing them)?
Data without science is nothing; just 1s and 0s, floating around a cloud waiting for someone to make sense of them. Data science is the process of extracting value from data, using advanced analytics tools. Enormous amounts of health information are being gathered every second, and we are rapidly getting better at decoding it: turning bytes into insights that can be used to improve the lives of patients. But the pace, methods and ethics of data science adoption varies dramatically between countries and regions. Why should we care about keeping up?